Skip to main content
. 2017 Sep 21;8(56):95662–95673. doi: 10.18632/oncotarget.21175

Figure 3. Overall survival in the cohort of patients with HGSOC samples (n=30) grouped according to the tumor PTPN13 expression level (≥ or < than the median IRS=8) assessed by immunohistochemistry.

Figure 3